Digital Biomarker Patents: Top Companies & Filing Trends 2026
Digital Biomarker Patents: Who Is Filing and Where the Field Is Still Open
65.2% of all 92 records sit with the top five assignees, so most of the claim space in scope is already occupied by a small group. Annual filings rose from 2 in 2017 to a peak of 16 in 2024, including the 2021-to-2024 span of +78% cited in the hero. The drop shown for 2025 and 2026 reflects publication lag of roughly 18 months rather than a real slowdown in filing.
- 1UNIVERSITY OF CHICAGO31
- 2NEUROGLEE THERAPEUTICS PTE LTD8
- 3JANSSEN PHARMA NV8
- 4JACKSON LAB THE7
- 5F HOFFMANN LA ROCHE & CO AG6
See the full digital biomarkers analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on digital biomarker patents
What counts as a digital biomarker patent in this dataset?
This dataset is scoped to records that combine a digital-biomarker, digital-endpoint or sensor-derived-measure concept with an explicit claim around measurement validity, analytical validation, clinical meaningfulness, data quality, device agnosticism or regulatory qualification. It excludes general wearable-device patents that do not address validation or regulatory qualification directly. As a result, the 92 records in scope are narrower than the full universe of digital-health or wearable-sensor patents.
Who are the leading patent holders in digital biomarkers?
Filing is concentrated: the top five assignees together hold 65.2% of all 92 records in scope, and the leading assignee alone holds 31 records. Below the top ten, which together hold 83.7% of records, filing counts drop quickly across the remaining companies in the 49-strong ranked list. That pattern means a small group of pharmaceutical, med-tech and digital-health platform companies account for most of the activity, with a long tail of single- or low-filing entrants behind them.
Is digital biomarker patent filing activity growing or slowing down?
Filings grew from 9 in 2021 to a peak of 16 in 2024, a 78% increase over that span, and 2024 is the most recent year the trend can treat as complete. The lower counts shown for 2025 and 2026 are an artefact of publication lag, since patent applications typically publish around 18 months after filing. On the evidence available, the field was still gaining filing volume through its last complete year rather than slowing.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Digital Biomarkers covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.